Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...
Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...
On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $51.48 which represents a decrease of $-1.75 or -3.29% from the prior close of $53.23. The stock opened at $53.14 and ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...
Investor's Business Daily on MSN6d
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' FlopGuardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.Please watch the video at Investors.com - Biotech Stocks Are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback